- Conditions
- Cancer
- Interventions
- cyclophosphamide, Cryoablation
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 5,942
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more
- Conditions
- Trigeminal Neuralgia
- Interventions
- Pain Diary use
- Other
- Lead sponsor
- Noema Pharma AG
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 30 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Dry Socket, Wound Infection
- Interventions
- Colgate Total Toothpaste, Colgate Regular Toothpaste
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Healthy
- Interventions
- Desloratadine
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Broadway, Florida
- Conditions
- Coagulation
- Interventions
- Whole Blood Clotting Time
- Device
- Lead sponsor
- Perosphere Technologies Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
- Conditions
- Schizophrenia, Bipolar Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
- Conditions
- Chronic Myelogenous Leukemia, Hematologic Malignancies
- Interventions
- Ponatinib
- Drug
- Lead sponsor
- Ariad Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- San Francisco, California • Ann Arbor, Michigan • Portland, Oregon + 2 more
- Conditions
- Pancreatic Cancer
- Interventions
- MRx0518, Hypofractionated Preoperative Radiation
- Drug · Radiation
- Lead sponsor
- 4D pharma plc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer, Lung Cancer
- Interventions
- Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
- Conditions
- Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
- Interventions
- Vitamin D3, Standard Vitamin D3 Supplementation
- Dietary Supplement
- Lead sponsor
- Phoenix Children's Hospital
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- Myeloid Leukemia, Chronic, Chronic-Phase
- Interventions
- dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Alhambra, California • Anaheim, California + 33 more
- Conditions
- Mouth Neoplasms
- Interventions
- Celecoxib, Calcitriol, Celecoxib plus Calcitriol
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Bone Diseases, Infectious
- Interventions
- Debio 1450
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- La Mesa, California • Butte, Montana
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
- Biological · Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sildenafil citrate
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
- Conditions
- Oral Mucositis
- Interventions
- Palifermin, Heparin
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Hypogonadism
- Interventions
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Antonio, Texas
- Conditions
- Contrast Induced Nephropathy
- Interventions
- Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate
- Other · Drug
- Lead sponsor
- The Western Pennsylvania Hospital
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Peanut Allergy
- Interventions
- AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
- Biological
- Lead sponsor
- Aimmune Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Intensity-Modulated Radiation Therapy, Peposertib
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 27
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
- Conditions
- Stroke
- Interventions
- WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Gout, Acute Gout Flare, Gout Flares
- Interventions
- ABP-745, Placebo
- Drug
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas